GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tharimmune Inc (NAS:THAR) » Definitions » Net Income

THAR (Tharimmune) Net Income : $-12.20 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Tharimmune Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Tharimmune's Net Income for the three months ended in Dec. 2024 was $-3.82 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-12.20 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Tharimmune's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-2.14.


Tharimmune Net Income Historical Data

The historical data trend for Tharimmune's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tharimmune Net Income Chart

Tharimmune Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income
Get a 7-Day Free Trial -2.42 -2.21 -8.47 -9.32 -12.20

Tharimmune Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.47 -2.26 -2.33 -3.80 -3.82

Tharimmune Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Tharimmune's Net Income for the fiscal year that ended in Dec. 2024 is calculated as

Net Income(A: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-12.198+0+0+0
=-12.20

Tharimmune's Net Income for the quarter that ended in Dec. 2024 is calculated as

Net Income(Q: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-3.821+0+0+0
=-3.82

Net Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tharimmune  (NAS:THAR) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Tharimmune's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Tharimmune Net Income Related Terms

Thank you for viewing the detailed overview of Tharimmune's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Tharimmune Business Description

Traded in Other Exchanges
N/A
Address
1200 Route 22 East, Suite 2000, Bridgewater, NJ, USA, 08807
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
Executives
Randy Milby director, officer: Chief Executive Officer 5 JACK LANE, NEWARK DE 19711
Sireesh Appajosyula director 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Kelly Anderson director C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
Leonard L Mazur director C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Sandeep Laumas 10 percent owner 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Thomas Hess officer: Chief Financial Officer 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Lynne A. Bui director 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Surender Kharbanda 10 percent owner 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Highpoint Pharmaceuticals Llc 10 percent owner 16192 COASTAL HIGHWAY, LEWES DE 19958
Kufe Llc 10 percent owner 179 GROVE STREET, WELLESLEY MA 02482
Varinder Kaur 10 percent owner 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807